The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch ...

Incyte will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference ...

Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

WuXi Biologics grants exclusive global rights of trispecific t-cell engager to Candid Therapeutics: Shanghai Wednesday, January 8, 2025, 15:00 Hrs [IST] WuXi Biologics, a leading ...

Plasmacytoid dendritic cells (pDC) primarily function as weak antigen-presenting cells (APC), but have also been shown to ...